p300/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancer

Cancer statistics, 2019

(2019) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non–small cell lung cancer

(2019) Bo Gong et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory

(2019) Mauro Poggio et al.   CELL

Cancer epigenetics: Moving forward

(2018) Angela Nebbioso et al.   PLoS Genetics

Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response

(2018) Gang Chen et al.   NATURE

A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression

(2018) Kathleen M. Mahoney et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The UCSC Genome Browser database: 2019 update

(2018) Maximilian Haeussler et al.   NUCLEIC ACIDS RESEARCH

Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA

(2017) Matthew A. Coelho et al.   IMMUNITY

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

(2017) Achim Rittmeyer et al.   LANCET

Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours

(2017) Loren M. Lasko et al.   NATURE

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

(2017) Angel Garcia-Diaz et al.   Cell Reports

Nuclear IRF-1 expression as a mechanism to assess “Capability” to express PD-L1 and response to PD-1 therapy in metastatic melanoma

(2017) James W. Smithy et al.   Journal for ImmunoTherapy of Cancer

The world of protein acetylation

(2016) Adrian Drazic et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

Microcystin-LR promotes cell proliferation in the mice liver by activating Akt and p38/ERK/JNK cascades

(2016) Jinghui Liu et al.   CHEMOSPHERE

BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression

(2016) Hengrui Zhu et al.   Cell Reports

HDACs and HDAC Inhibitors in Cancer Development and Therapy

(2016) Yixuan Li et al.   Cold Spring Harbor Perspectives in Medicine

The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer

(2015) H. Gevensleben et al.   CLINICAL CANCER RESEARCH

Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future

(2015) Lieping Chen et al.   JOURNAL OF CLINICAL INVESTIGATION

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance

(2015) A M Martin et al.   PROSTATE CANCER AND PROSTATIC DISEASES

Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis

(2015) Francesco Massari et al.   Targeted Oncology

p300 Acetyltransferase Regulates Androgen Receptor Degradation and PTEN-Deficient Prostate Tumorigenesis

(2014) Jian Zhong et al.   CANCER RESEARCH

Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer

(2014) Irfan A. Asangani et al.   NATURE

Emerging mechanisms of enzalutamide resistance in prostate cancer

(2014) Frank Claessens et al.   Nature Reviews Urology

EZH2, an epigenetic driver of prostate cancer

(2013) Yeqing Angela Yang et al.   Protein & Cell

Cancer Epigenetics: From Mechanism to Therapy

(2012) Mark A. Dawson et al.   CELL

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Drug resistance in metastatic castration-resistant prostate cancer

(2010) Bostjan Seruga et al.   Nature Reviews Clinical Oncology